盟科药业拟定增募资10.33亿元 实控人将发生变更

Group 1 - The company Mengke Pharmaceutical (688373) plans to raise up to 1.033 billion yuan through a private placement at a price of 6.3 yuan per share, with all proceeds allocated for daily R&D and operational investments [1] - After the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke Pharmaceutical, becoming the controlling shareholder, while Zhang Xiantao will become the actual controller of the company [1] - Mengke Pharmaceutical focuses on developing innovative treatments for common and severe drug-resistant bacterial infections, with its core product MRX-4 having received acceptance from the National Medical Products Administration as of June 30, 2025 [1] Group 2 - The company has seen significant sales growth, with product sales revenue increasing by 88.31% and 43.51% for the fiscal years 2022-2023 and 2023-2024 respectively, and a 10.26% year-on-year growth in the first half of 2025 [1] - Despite the sales growth, the company faces limitations in its sales team’s coverage of terminal hospitals, necessitating external support to enhance commercialization efficiency [2] - Mengke Pharmaceutical currently lacks production capabilities, relying entirely on Huahai Pharmaceutical (600521) for contract manufacturing, which may hinder profitability [2] Group 3 - Haiqing Pharmaceutical is a research-driven modern pharmaceutical enterprise focused on formulation business development, which can enhance Mengke Pharmaceutical's production and R&D capabilities [2] - The financing aims to integrate industry resources and bring in a strong sales-oriented investor to improve the company's commercialization capabilities and expand sales scale [2]